Inhibitory effects of dioscin on cytochrome P450 enzymes

Abstract

Dioscin, a natural product, shows various pharmacological activities. However, the drug-drug interaction (DDI) potential of dioscin via the inhibition of cytochrome P450 (CYP) enzymes is still unknown. In this paper, the inhibitory effects of dioscin on six major CYP isoforms (1A2, 2A6, 2C9, 2D6, 2E1 and 3A4) were investigated. Using human liver microsomes (HLM), we found that dioscin inhibited the activities of CYP2C9, CYP2E1 and CYP3A4, with IC 50 values of 22.60, 17.40 and 12.59 mM, respectively. Further research indicated that dioscin was a typical competitive inhibitor for CYP2C9, CYP2E1 and CYP3A4 (K i ¼ 5.0, 10.4 and 15.5 mM, respectively), as demonstrated by Lineweaver-Burk plots. In addition, dioscin exhibited time-and NADPH-dependent inhibitions of CYP3A4, and weak inhibitions of CYP1A2, CYP2A6 and CYP2D6 were also observed. In cell and animal experiments, dioscin markedly down-regulated the protein expressions of CYP2C9, CYP2E1 and CYP3A4 in primary rat hepatocytes and livers in a dosedependent manner. This is the first paper on the inhibitory effects of dioscin on CYP in HLMs to predict the potential for dioscin-drug interaction and toxicity. Nevertheless, the clinical significance of the data presented herein should be further evaluated with in vivo research.

Ternary copper(II) complex: NCI60 screening, toxicity studies, and evaluation of efficacy in xenograft models of nasopharyngeal carcinoma

“…Assessment for potential drug-drug interaction is an important component of drug discovery and development [ 36 ]. About 25% of adverse drug reactions were caused by drug-drug interactions [ 36 ].…”

“…Assessment for potential drug-drug interaction is an important component of drug discovery and development [ 36 ]. About 25% of adverse drug reactions were caused by drug-drug interactions [ 36 ]. Most drug-drug interaction and drug metabolism occur in the hepatic cytochrome P450 (CYP) system [ 37 ].…”

In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes

“…Most CYP enzymes can be inhibited or induced by a variety of drugs and chemicals that can give rise to toxicity or treatment failure, and many herb-drug interactions have been generated from the concurrent use of herbal prescription and over-the-counter drugs (Yang et al 2012;Lee et al 2013). St. John's wort, Ginkgo, Ginseng, and licorice have all been reported to interact with anticoagulants, antiretroviral drugs, anticancer drugs, immunosuppressants or antidepressants (Unger 2013;Meng & Liu 2014;Pirotta et al 2014;Tao et al 2014;Wang et al 2015). As ampelopsis-grossedentata tea may be drunk by people every day, and therefore, the effects of DHM on the activity of CYP enzymes should be investigated.…”

Potential Effects of Ibuprofen, Remdesivir and Omeprazole on Dexamethasone Metabolism in Control Sprague Dawley Male Rat Liver Microsomes (Drugs Often Used Together Alongside COVID-19 Treatment)

“…The drug-metabolizing enzyme system, also known as the CYP450s superfamily, is responsible for the biotransformation of a large number of endogenous (fatty acids, hormones, bile acids, steroids, prostaglandins) and exogenous compounds (toxic chemicals, carcinogens, drugs, organic solvents, environmental pollutants) [ 1 ]. The use of a combination of medicine can result in potential drug–drug interactions, which, in turn, can change the drug metabolism in both Phase I and Phase II [ 2 ]. Many drug–drug interactions change the pharmacokinetic behaviour of the drugs in addition to the drug’s bioavailability (absorption, distribution, and elimination) [ 2 ].…”

“…The use of a combination of medicine can result in potential drug–drug interactions, which, in turn, can change the drug metabolism in both Phase I and Phase II [ 2 ]. Many drug–drug interactions change the pharmacokinetic behaviour of the drugs in addition to the drug’s bioavailability (absorption, distribution, and elimination) [ 2 ]. In the majority of cases, the detoxification of the substrate occurs due to the action of CYP450, either as a direct effect or through the phase II enzyme’s actions.…”